Is the occurrence of higher adverse effects associated with better oncological outcome in metastatic urothelial carcinoma patients treated with pembrolizumab?

被引：0
|
作者：
Hayakawa, Nozomi
Kikuchi, Eiji
Ogihara, Koichirou
Hattori, Seiya
Yoshimine, Shunsuke
Shirotake, Suguru
Okabe, Takashi
Yamashita, Ryo
Oya, Mototsugu
机构：
[1] Keio Univ, Dept Urol, Sch Med, Tokyo, Japan
[2] Kawasaki Municipal Hosp, Kawasaki, Kanagawa, Japan
[3] Saitama City Hosp, Saitama, Japan
[4] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[5] Shizuoka Canc Ctr, Shizuoka, Japan
[6] Keio Univ, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.405
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
405
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PROTON PUMP INHIBITOR USE IS A NEGATIVE PROGNOSTIC FACTOR FOR METASTATIC UROTHELIAL CARCINOMA PROGRESSION IN PEMBROLIZUMAB-TREATED PATIENTS
    Iida, Keitaro
    Nagai, Takashi
    Nozaki, Satoshi
    Etani, Toshiki
    Naiki, Taku
    Nakane, Akihiro
    Akita, Hidetoshi
    Kubota, Hiroki
    Kamiya, Hiroyuki
    Kawai, Noriyasu
    Yasui, Takahiro
    JOURNAL OF UROLOGY, 2021, 206 : E766 - E767
  • [22] Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy
    Gierth, M.
    Mayr, R.
    Aziz, A.
    Krieger, S.
    Wullich, B.
    Pycha, A.
    Lodde, M.
    Salvadori, U.
    Bruendl, J.
    Fritsche, H. M.
    Hofstaedter, F.
    Pawlik, M. T.
    Otto, W.
    May, M.
    Burger, M.
    Denzinger, S.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (10) : 1819 - 1826
  • [23] Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy
    M. Gierth
    R. Mayr
    A. Aziz
    S. Krieger
    B. Wullich
    A. Pycha
    M. Lodde
    U. Salvadori
    J. Bründl
    H. M. Fritsche
    F. Hofstädter
    M. T. Pawlik
    W. Otto
    M. May
    M. Burger
    S. Denzinger
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 1819 - 1826
  • [24] TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
    Mollica, Veronica
    Tassinari, Elisa
    Santoni, Matteo
    Marchese, Paola Valeria
    Giunchi, Francesca
    Maloberti, Thais
    Tateo, Valentina
    Ricci, Costantino
    Rosellini, Matteo
    Marchetti, Andrea
    Fiorentino, Michelangelo
    De Biase, Dario
    Massari, Francesco
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 253
  • [25] Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma
    Fukuokaya, Wataru
    Kimura, Takahiro
    Yanagisawa, Takafumi
    Kimura, Shoji
    Tsuzuki, Shunsuke
    Koike, Yuhei
    Iwamoto, Yuya
    Enei, Yuki
    Tanaka, Masatoshi
    Urabe, Fumihiko
    Onuma, Hajime
    Honda, Mariko
    Miki, Jun
    Oyama, Yu
    Abe, Hirokazu
    Egawa, Shin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (01) : 229 - 236
  • [26] Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma
    Wataru Fukuokaya
    Takahiro Kimura
    Takafumi Yanagisawa
    Shoji Kimura
    Shunsuke Tsuzuki
    Yuhei Koike
    Yuya Iwamoto
    Yuki Enei
    Masatoshi Tanaka
    Fumihiko Urabe
    Hajime Onuma
    Mariko Honda
    Jun Miki
    Yu Oyama
    Hirokazu Abe
    Shin Egawa
    Targeted Oncology, 2021, 16 : 189 - 196
  • [27] Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma
    Fukuokaya, Wataru
    Kimura, Takahiro
    Yanagisawa, Takafumi
    Kimura, Shoji
    Tsuzuki, Shunsuke
    Koike, Yuhei
    Iwamoto, Yuya
    Enei, Yuki
    Tanaka, Masatoshi
    Urabe, Fumihiko
    Onuma, Hajime
    Honda, Mariko
    Miki, Jun
    Oyama, Yu
    Abe, Hirokazu
    Egawa, Shin
    TARGETED ONCOLOGY, 2021, 16 (02) : 189 - 196
  • [28] Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma
    Wataru Fukuokaya
    Takahiro Kimura
    Takafumi Yanagisawa
    Shoji Kimura
    Shunsuke Tsuzuki
    Yuhei Koike
    Yuya Iwamoto
    Yuki Enei
    Masatoshi Tanaka
    Fumihiko Urabe
    Hajime Onuma
    Mariko Honda
    Jun Miki
    Yu Oyama
    Hirokazu Abe
    Shin Egawa
    Cancer Immunology, Immunotherapy, 2022, 71 : 229 - 236
  • [29] Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction
    Kita, Yuki
    Ito, Katsuhiro
    Kanda, Sohei
    Joraku, Akira
    Yamaguchi, Ritsuki
    Shimizu, Yosuke
    Hayata, Naoki
    Somiya, Shinya
    Shibasaki, Noboru
    Kimura, Takahiro
    Hikami, Kensuke
    Yamada, Takeshi
    Abe, Takashige
    Tsuchihashi, Kazunari
    Tatarano, Shuichi
    Nishiyama, Hiroyuki
    Kitamura, Hiroshi
    Kobayashi, Takashi
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (09) : 410.e11 - 410.e18
  • [30] Determination of Circulating tumor DNA alterations in advanced urothelial carcinoma patients treated with pembrolizumab
    Tanuma, Kozaburo
    Kojima, Takahiro
    Shiga, Masanobu
    Kandori, Shuya
    Kimura, Tomokazu
    Kawahara, Takashi
    Negoro, Hiromitsu
    Nishiyama, Hiroyuki
    CANCER SCIENCE, 2021, 112 : 872 - 872
12345